Biopsy-based algorithm found accurate for small renal masses

February 9, 2013
Biopsy-based algorithm found accurate for small renal masses
Compared with final pathology, biopsy of small renal masses can be accurately used in a treatment algorithm to direct management, according to research published in the February issue of The Journal of Urology.

(HealthDay)—Compared with final pathology, biopsy of small renal masses (SRMs) can be accurately used in a treatment algorithm to direct management, according to research published in the February issue of The Journal of Urology.

Schuyler J. Halverson, M.D., of the University of Michigan Health System in Ann Arbor, and colleagues assessed the accuracy of a biopsy-directed treatment algorithm for correctly assigning 133 patients with SRMs (≤4 cm) to treatment or active surveillance.

Using a biopsy-directed treatment algorithm, 36 patients with SRMs were assigned to surveillance and 97 were treated. Based on the final , the researchers found that 31 percent of those patients for whom surveillance was recommended should have received treatment, while no patients moved from treatment to surveillance. Seven of the 11 misclassified cases had a biopsy indicative of grade 1 clear cell , which was upgraded to grade 2 or 3. Overall agreement between biopsy and final pathology was 92 percent; however, after adjustment of the algorithm to avoid undergrading of clear cell renal cancer, agreement improved to 97 percent, with negative and positive predictive values of 0.86 and 1.0, respectively.

"Image guided, percutaneous renal mass biopsy is highly accurate for diagnosis in most patients and provides valuable information to guide the management of SRM," the authors write. "We have shown that although slight may exist between initial biopsy and final pathology due to the heterogeneous nature of some tumors, this variability becomes clinically irrelevant when using a well-defined management protocol."

More information: Abstract
Full Text

Related Stories

Criteria for surveillance of small renal mass examined

May 7, 2012

(HealthDay) -- Active surveillance of patients with small renal masses is driven by a tumor size less than 3 cm, poor performance score (PS), and an endophytic lesion, among other patient, tumor, and surgeon characteristics, ...

Active surveillance cost-effective for prostate cancer

July 13, 2012

(HealthDay) -- In a theoretical cohort of 120,000 men, selecting active surveillance for prostate cancer results in considerable cost savings at five and 10 years of follow-up, compared with immediate treatment, according ...

Recommended for you

Experimental MERS vaccine shows promise in animal studies

July 28, 2015

A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines. ...

Can social isolation fuel epidemics?

July 21, 2015

Conventional wisdom has it that the more people stay within their own social groups and avoid others, the less likely it is small disease outbreaks turn into full-blown epidemics. But the conventional wisdom is wrong, according ...

Lack of knowledge on animal disease leaves humans at risk

July 20, 2015

Researchers from the University of Sydney have painted the most detailed picture to date of major infectious diseases shared between wildlife and livestock, and found a huge gap in knowledge about diseases which could spread ...

IBD genetically similar in Europeans and non-Europeans

July 20, 2015

The first genetic study of inflammatory bowel disease (IBD) to include individuals from diverse populations has shown that the regions of the genome underlying the disease are consistent around the world. This study, conducted ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.